Ignite Creation Date:
2025-12-25 @ 1:31 AM
Ignite Modification Date:
2026-03-22 @ 7:58 AM
Study NCT ID:
NCT06123494
Status:
RECRUITING
Last Update Posted:
2024-01-16
First Post:
2023-11-06
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
SHR-A1811-308
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None